Literature DB >> 19445748

Schizophrenia (maintenance treatment).

Thomas E Smith1, Christi A Weston, Jeffrey A Lieberman.   

Abstract

INTRODUCTION: One in a hundred people will develop schizophrenia; about 75% of people have relapses and continued disability, and a third fail to respond to standard treatment. Positive symptoms include auditory hallucinations, delusions, and thought disorder. Negative symptoms (demotivation, self-neglect, and reduced emotion) have not been consistently improved by any treatment. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: Which interventions reduce relapse; and improve adherence rates? Which interventions are effective in people resistant to standard antipsychotic drugs? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2007 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 45 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: behavioural therapy, clozapine, cognitive behavioural therapy (CBT), compliance therapy, continuation of antipsychotic drugs (reduce relapse rates), first-generation antipsychotic drugs in treatment-resistant people, multiple-session family interventions, psychoeducational interventions, second-generation antipsychotic drugs in treatment-resistant people, and social-skills training.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19445748      PMCID: PMC2907810     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  31 in total

1.  Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation.

Authors:  S Pilling; P Bebbington; E Kuipers; P Garety; J Geddes; B Martindale; G Orbach; C Morgan
Journal:  Psychol Med       Date:  2002-07       Impact factor: 7.723

Review 2.  Phenotype of schizophrenia: a review and formulation.

Authors:  C A Tamminga; H H Holcomb
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

3.  Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study.

Authors:  A Jablensky; N Sartorius; G Ernberg; M Anker; A Korten; J E Cooper; R Day; A Bertelsen
Journal:  Psychol Med Monogr Suppl       Date:  1992

4.  Effects of a mutual support group for families of Chinese people with schizophrenia: 18-month follow-up.

Authors:  Wai-Tong Chien; Sally W C Chan; David R Thompson
Journal:  Br J Psychiatry       Date:  2006-07       Impact factor: 9.319

5.  Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

Authors:  Martin Dossenbach; Cesar Arango-Dávila; Hernan Silva Ibarra; Eric Landa; Jaime Aguilar; Osvaldo Caro; Joanna Leadbetter; Sheila Assunção
Journal:  J Clin Psychiatry       Date:  2005-08       Impact factor: 4.384

6.  Neuroleptic compliance among chronic schizophrenic outpatients: an intervention outcome report.

Authors:  J A Boczkowski; A Zeichner; N DeSanto
Journal:  J Consult Clin Psychol       Date:  1985-10

7.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

8.  Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy.

Authors:  S Pilling; P Bebbington; E Kuipers; P Garety; J Geddes; G Orbach; C Morgan
Journal:  Psychol Med       Date:  2002-07       Impact factor: 7.723

9.  Evaluation of an instructional program for improving medication compliance for chronically mentally ill outpatients.

Authors:  N H Azrin; G Teichner
Journal:  Behav Res Ther       Date:  1998-09

10.  Sex differences in the risk of schizophrenia: evidence from meta-analysis.

Authors:  Andre Aleman; René S Kahn; Jean-Paul Selten
Journal:  Arch Gen Psychiatry       Date:  2003-06
View more
  1 in total

1.  A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future.

Authors:  Leslie Citrome; Joseph P McEvoy; Mark S Todtenkopf; David McDonnell; Peter J Weiden
Journal:  Neuropsychiatr Dis Treat       Date:  2019-09-05       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.